|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GLMP |
Gene summary for GLMP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GLMP | Gene ID | 112770 |
| Gene name | glycosylated lysosomal membrane protein | |
| Gene Alias | C1orf85 | |
| Cytomap | 1q22 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A087WV34 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 112770 | GLMP | C30 | Human | Oral cavity | OSCC | 1.91e-36 | 1.42e+00 | 0.3055 |
| 112770 | GLMP | C38 | Human | Oral cavity | OSCC | 1.05e-09 | 7.96e-01 | 0.172 |
| 112770 | GLMP | C43 | Human | Oral cavity | OSCC | 4.07e-05 | 1.85e-01 | 0.1704 |
| 112770 | GLMP | C46 | Human | Oral cavity | OSCC | 7.01e-07 | 2.44e-01 | 0.1673 |
| 112770 | GLMP | C51 | Human | Oral cavity | OSCC | 4.20e-15 | 6.66e-01 | 0.2674 |
| 112770 | GLMP | C57 | Human | Oral cavity | OSCC | 1.46e-04 | 2.95e-01 | 0.1679 |
| 112770 | GLMP | C06 | Human | Oral cavity | OSCC | 2.11e-11 | 1.19e+00 | 0.2699 |
| 112770 | GLMP | C07 | Human | Oral cavity | OSCC | 1.99e-06 | 1.18e+00 | 0.2491 |
| 112770 | GLMP | C08 | Human | Oral cavity | OSCC | 6.01e-37 | 7.07e-01 | 0.1919 |
| 112770 | GLMP | C09 | Human | Oral cavity | OSCC | 1.07e-06 | 2.87e-01 | 0.1431 |
| 112770 | GLMP | LN38 | Human | Oral cavity | OSCC | 4.35e-02 | 9.05e-01 | 0.168 |
| 112770 | GLMP | LP15 | Human | Oral cavity | LP | 1.10e-02 | 9.19e-01 | 0.2174 |
| 112770 | GLMP | LP17 | Human | Oral cavity | LP | 8.16e-03 | 5.06e-01 | 0.2349 |
| 112770 | GLMP | SYSMH1 | Human | Oral cavity | OSCC | 7.95e-04 | 1.09e-01 | 0.1127 |
| 112770 | GLMP | SYSMH2 | Human | Oral cavity | OSCC | 1.72e-10 | 3.46e-01 | 0.2326 |
| 112770 | GLMP | SYSMH3 | Human | Oral cavity | OSCC | 4.24e-20 | 4.51e-01 | 0.2442 |
| 112770 | GLMP | SYSMH6 | Human | Oral cavity | OSCC | 1.57e-06 | 2.38e-01 | 0.1275 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003164727 | Esophagus | HGIN | regulation of protein stability | 96/2587 | 298/18723 | 2.21e-16 | 5.76e-14 | 96 |
| GO:005082127 | Esophagus | HGIN | protein stabilization | 64/2587 | 191/18723 | 3.11e-12 | 4.24e-10 | 64 |
| GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
| GO:0050821111 | Esophagus | ESCC | protein stabilization | 140/8552 | 191/18723 | 6.50e-15 | 3.61e-13 | 140 |
| GO:00726659 | Esophagus | ESCC | protein localization to vacuole | 52/8552 | 67/18723 | 9.14e-08 | 1.52e-06 | 52 |
| GO:00614626 | Esophagus | ESCC | protein localization to lysosome | 34/8552 | 46/18723 | 9.39e-05 | 6.70e-04 | 34 |
| GO:003164712 | Liver | Cirrhotic | regulation of protein stability | 144/4634 | 298/18723 | 6.74e-19 | 1.28e-16 | 144 |
| GO:005082112 | Liver | Cirrhotic | protein stabilization | 97/4634 | 191/18723 | 6.67e-15 | 6.97e-13 | 97 |
| GO:007266511 | Liver | Cirrhotic | protein localization to vacuole | 37/4634 | 67/18723 | 9.11e-08 | 2.66e-06 | 37 |
| GO:00614622 | Liver | Cirrhotic | protein localization to lysosome | 24/4634 | 46/18723 | 5.75e-05 | 6.58e-04 | 24 |
| GO:003164722 | Liver | HCC | regulation of protein stability | 211/7958 | 298/18723 | 2.29e-23 | 5.01e-21 | 211 |
| GO:005082122 | Liver | HCC | protein stabilization | 139/7958 | 191/18723 | 1.61e-17 | 1.71e-15 | 139 |
| GO:007266521 | Liver | HCC | protein localization to vacuole | 48/7958 | 67/18723 | 1.27e-06 | 1.85e-05 | 48 |
| GO:00614621 | Liver | HCC | protein localization to lysosome | 33/7958 | 46/18723 | 5.63e-05 | 5.26e-04 | 33 |
| GO:003164720 | Oral cavity | OSCC | regulation of protein stability | 193/7305 | 298/18723 | 1.30e-19 | 1.95e-17 | 193 |
| GO:005082120 | Oral cavity | OSCC | protein stabilization | 122/7305 | 191/18723 | 2.69e-12 | 1.09e-10 | 122 |
| GO:00726658 | Oral cavity | OSCC | protein localization to vacuole | 44/7305 | 67/18723 | 8.92e-06 | 9.44e-05 | 44 |
| GO:00614625 | Oral cavity | OSCC | protein localization to lysosome | 28/7305 | 46/18723 | 2.19e-03 | 9.95e-03 | 28 |
| GO:0031647110 | Oral cavity | LP | regulation of protein stability | 132/4623 | 298/18723 | 8.16e-14 | 7.99e-12 | 132 |
| GO:0050821110 | Oral cavity | LP | protein stabilization | 88/4623 | 191/18723 | 9.15e-11 | 5.51e-09 | 88 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GLMP | SNV | Missense_Mutation | c.856N>A | p.Ala286Thr | p.A286T | Q8WWB7 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
| GLMP | SNV | Missense_Mutation | c.1009G>A | p.Gly337Arg | p.G337R | Q8WWB7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A07O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | CR | ||
| GLMP | SNV | Missense_Mutation | c.1191N>T | p.Lys397Asn | p.K397N | Q8WWB7 | protein_coding | deleterious(0.04) | benign(0.429) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| GLMP | insertion | In_Frame_Ins | novel | c.863_864insTATGTT | p.Ser288_Gln289insMetPhe | p.S288_Q289insMF | Q8WWB7 | protein_coding | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
| GLMP | insertion | Frame_Shift_Ins | novel | c.862_863insTTTCGATTTATTTTTATTTTTTTAGAGACATGGTCTTG | p.Ser288PhefsTer35 | p.S288Ffs*35 | Q8WWB7 | protein_coding | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
| GLMP | insertion | Nonsense_Mutation | novel | c.741_742insACCACAAGAAGTACTCAGAGTACCAGTCCATAAATTAAGG | p.Pro248ThrfsTer11 | p.P248Tfs*11 | Q8WWB7 | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD | ||
| GLMP | SNV | Missense_Mutation | c.830N>T | p.Ser277Leu | p.S277L | Q8WWB7 | protein_coding | tolerated(0.26) | benign(0.003) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| GLMP | SNV | Missense_Mutation | rs749570618 | c.1058C>T | p.Ser353Leu | p.S353L | Q8WWB7 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| GLMP | SNV | Missense_Mutation | novel | c.1045N>G | p.Tyr349Asp | p.Y349D | Q8WWB7 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| GLMP | SNV | Missense_Mutation | c.119N>G | p.Gln40Arg | p.Q40R | Q8WWB7 | protein_coding | tolerated(0.1) | benign(0.013) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |